Cargando…

What will it take for an injectable ARV to change the face of the HIV epidemic in high‐prevalence countries? Considerations regarding drug costs and operations

INTRODUCTION: The proven effectiveness of injectable cabotegravir (CAB‐LA) is higher than that of any other HIV prevention intervention ever trialled or implemented, surpassing medical male circumcision, condoms and combination antiretroviral treatment. Based on our own analyses and experience with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meyer‐Rath, Gesine, Jamieson, Lise, Pillay, Yogan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338998/ https://www.ncbi.nlm.nih.gov/pubmed/37439062 http://dx.doi.org/10.1002/jia2.26106

Ejemplares similares

When donor funding leaves: an interrupted time-series analysis of the impact of integrating direct HIV care and treatment into public health services in a region of Johannesburg
por: Lince-Deroche, Naomi, et al.
Publicado: (2019)

The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa
por: Meyer-Rath, Gesine, et al.
Publicado: (2012)

New ARV drugs
por: Gulick, Roy
Publicado: (2014)

Considerations and concerns regarding the readiness to remove face coverings
por: Terada, Mari, et al.
Publicado: (2022)

Inpatient Care Costs of COVID-19 in South Africa’s Public Healthcare System
por: Edoka, Ijeoma, et al.
Publicado: (2021)

Development of long-acting ARV’s
por: Boffito, Marta
Publicado: (2014)

Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case
por: Meyer-Rath, Gesine, et al.
Publicado: (2017)

Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis
por: Jamieson, Lise, et al.
Publicado: (2022)

It can be dangerous to take epidemic curves of COVID-19 at face value
por: Burstyn, Igor, et al.
Publicado: (2020)

ARV regimen choice and co-morbidities
por: Peters, Barry
Publicado: (2014)

Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered?
por: Chiu, Calvin, et al.
Publicado: (2017)

Changing the South African national antiretroviral therapy guidelines: The role of cost modelling
por: Meyer-Rath, Gesine, et al.
Publicado: (2017)

Taking digital health innovation to scale in South Africa: ten lessons from MomConnect
por: Peter, Joanne, et al.
Publicado: (2018)

Antiretroviral (ARV) Therapy in Resource Poor Countries: What do we Need in Real Life?
por: Castelli, Francesco, et al.
Publicado: (2010)

The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case
por: Meyer-Rath, Gesine, et al.
Publicado: (2019)

Considerations Regarding Autologus Blood Injection for Tennis Elbow Tendinopathy
por: Khan, Hayat Ahmad, et al.
Publicado: (2014)

What will it take for the Global Plan priority countries in Sub-Saharan Africa to eliminate mother-to-child transmission of HIV?
por: Goga, Ameena E., et al.
Publicado: (2019)

Women and ARV-based prevention: opportunities and challenges
por: Geary, Cynthia W, et al.
Publicado: (2014)

Operational considerations for the PSB H- Injection System
por: Weterings, W, et al.
Publicado: (2009)

Cost and impact of scaling up interventions to save lives of mothers and children: taking South Africa closer to MDGs 4 and 5
por: Chola, Lumbwe, et al.
Publicado: (2015)

Coccydynia: anatomic origin and considerations regarding the effectiveness of injections for pain management
por: Lee, Shin-Hyo, et al.
Publicado: (2023)

Antiretroviral (ARV) Drug Resistance and HIV-1 Subtypes among Injecting Drug Users in the Coastal Region of Kenya
por: Ng'ong'a, Gabriel O., et al.
Publicado: (2022)

Patent Pools for ARVs: Industry Perspectives from ASPEN
por: Nicolaou, Stavros
Publicado: (2010)

Women and ARV-based HIV prevention – challenges and opportunities
por: Geary, Cynthia W, et al.
Publicado: (2014)

Environmental Risk Characterization of an Antiretroviral (ARV) Lamivudine in Ecosystems
por: Omotola, Elizabeth Oyinkansola, et al.
Publicado: (2021)

Recombinant Newcastle Disease Virus (NDV) Expressing Sigma C Protein of Avian Reovirus (ARV) Protects against Both ARV and NDV in Chickens
por: Saikia, Deep Prakash, et al.
Publicado: (2019)

A quantitative assessment of the consistency of projections from five mathematical models of the HIV epidemic in South Africa: a model comparison study
por: Moolla, Haroon, et al.
Publicado: (2023)

Role of data from cost and other economic analyses in healthcare decision-making for HIV, TB and sexual/reproductive health programmes in South Africa
por: Murphy, Joshua P, et al.
Publicado: (2021)

ARV formulated microbicides big promise; as world waits vaccine
por: Ondari, Ronald Orutwa, et al.
Publicado: (2009)

The clinic-biological progress of patients on ARV under D.O.T
por: Lyli, O, et al.
Publicado: (2009)

ARV-based HIV prevention for women – where we are in 2014
por: Mastro, Timothy D, et al.
Publicado: (2014)

Strategies to reduce risks in ARV supply chains in the developing world
por: Larson, Chris, et al.
Publicado: (2014)

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients
por: Baril, Jean-Guy, et al.
Publicado: (2016)

The role of modelling and analytics in South African COVID-19 planning and budgeting
por: Meyer-Rath, Gesine, et al.
Publicado: (2023)

Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025
por: Gupta, Aastha, et al.
Publicado: (2016)

“Knowledge and practices of HIV infected patients regarding medicine disposal among patients attending public ARV clinics in KwaZulu Natal, South Africa”
por: Maharaj, Pooja, et al.
Publicado: (2020)

World AIDS Day 2020: Reflections on global and South African progress and continuing challenges
por: Pillay, Yogan, et al.
Publicado: (2021)

The ARV roll out and the disability grant: a South African dilemma?
por: de Paoli, Marina Manuela, et al.
Publicado: (2012)

Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics
por: Dionisio, Daniele, et al.
Publicado: (2010)

Pooling ARV Drug Patents: A Pro-Access Fitting Strategy?
por: Dionisio, Daniele
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9u3pthk7qcq2bb8915vp93dqlj